FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023342930> ?p ?o ?g. }

• W2023342930 endingPage "19" @default.
• W2023342930 startingPage "13" @default.
• W2023342930 abstract "Background: TRA-8 is a murine agonist monoclonal antibody to death receptor 5 (DR5), which is able to trigger apoptosis in DR5 positive human tumor cells without the aid of crosslinking. It has demonstrated cytotoxicity in vitro and in vivo antitumor efficacy to a wide range of solid tumors in murine xenograft models. Tigatuzumab is a humanized IgG1 monoclonal antibody derived from TRA-8. Methods: A phase I trial of tigatuzumab in patients with relapsed/refractory carcinomas (n = 16) or lymphoma (n = 1) was designed to determine the maximal tolerated dose (MTD), pharmacokinetics, immunogenicity, and safety. Three to six (3–6) patients were enrolled in successive escalating cohorts at doses ranging from 1 to 8 mg/kg weekly. Results: Seventeen (17) patients enrolled, 9 in the 1-, 2-, and 4-mg/kg dose cohorts (3 in each cohort) and 8 in the 8-mg/kg dose cohort. Tigatuzumab was well tolerated with no DLTs observed, and the MTD was not reached. There were no study-drug–related grade 3 or 4, renal, hepatic, or hematologic toxicities. Plasma half-life was 6–10 days, and no anti-tigatuzumab responses were detected. Seven (7) patients had stable disease, with the duration of response ranging from 81 to 798 days. Conclusions: Tigatuzumab is well tolerated, and the MTD was not reached. The high number of patients with stable disease suggests antitumor activity." @default.
• W2023342930 created "2016-06-24" @default.
• W2023342930 creator A5005234747 @default.
• W2023342930 creator A5011260995 @default.
• W2023342930 creator A5012750761 @default.
• W2023342930 creator A5030650996 @default.
• W2023342930 creator A5041464341 @default.
• W2023342930 creator A5057254430 @default.
• W2023342930 creator A5073064208 @default.
• W2023342930 creator A5077011628 @default.
• W2023342930 creator A5087541775 @default.
• W2023342930 creator A5088868208 @default.
• W2023342930 date "2010-02-01" @default.
• W2023342930 modified "2023-10-16" @default.
• W2023342930 title "Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)" @default.
• W2023342930 cites W1912693401 @default.
• W2023342930 cites W1924370554 @default.
• W2023342930 cites W1964646881 @default.
• W2023342930 cites W1984709119 @default.
• W2023342930 cites W1995960781 @default.
• W2023342930 cites W2040661552 @default.
• W2023342930 cites W2068711271 @default.
• W2023342930 cites W2074106785 @default.
• W2023342930 cites W2074123379 @default.
• W2023342930 cites W2080613199 @default.
• W2023342930 cites W2081211388 @default.
• W2023342930 cites W2100204192 @default.
• W2023342930 cites W2101922134 @default.
• W2023342930 cites W2102986716 @default.
• W2023342930 cites W2103939202 @default.
• W2023342930 cites W2106284224 @default.
• W2023342930 cites W2109097295 @default.
• W2023342930 cites W2115919161 @default.
• W2023342930 cites W2117087670 @default.
• W2023342930 cites W2119501278 @default.
• W2023342930 cites W2130988210 @default.
• W2023342930 cites W2139248078 @default.
• W2023342930 cites W2159999972 @default.
• W2023342930 cites W2161153456 @default.
• W2023342930 cites W3021180038 @default.
• W2023342930 doi "https://doi.org/10.1089/cbr.2009.0673" @default.
• W2023342930 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2883819" @default.
• W2023342930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20187792" @default.
• W2023342930 hasPublicationYear "2010" @default.
• W2023342930 type Work @default.
• W2023342930 sameAs 2023342930 @default.
• W2023342930 citedByCount "125" @default.
• W2023342930 countsByYear W20233429302012 @default.
• W2023342930 countsByYear W20233429302013 @default.
• W2023342930 countsByYear W20233429302014 @default.
• W2023342930 countsByYear W20233429302015 @default.
• W2023342930 countsByYear W20233429302016 @default.
• W2023342930 countsByYear W20233429302017 @default.
• W2023342930 countsByYear W20233429302018 @default.
• W2023342930 countsByYear W20233429302019 @default.
• W2023342930 countsByYear W20233429302020 @default.
• W2023342930 countsByYear W20233429302021 @default.
• W2023342930 countsByYear W20233429302022 @default.
• W2023342930 countsByYear W20233429302023 @default.
• W2023342930 crossrefType "journal-article" @default.
• W2023342930 hasAuthorship W2023342930A5005234747 @default.
• W2023342930 hasAuthorship W2023342930A5011260995 @default.
• W2023342930 hasAuthorship W2023342930A5012750761 @default.
• W2023342930 hasAuthorship W2023342930A5030650996 @default.
• W2023342930 hasAuthorship W2023342930A5041464341 @default.
• W2023342930 hasAuthorship W2023342930A5057254430 @default.
• W2023342930 hasAuthorship W2023342930A5073064208 @default.
• W2023342930 hasAuthorship W2023342930A5077011628 @default.
• W2023342930 hasAuthorship W2023342930A5087541775 @default.
• W2023342930 hasAuthorship W2023342930A5088868208 @default.
• W2023342930 hasBestOaLocation W20233429302 @default.
• W2023342930 hasConcept C112705442 @default.
• W2023342930 hasConcept C126322002 @default.
• W2023342930 hasConcept C142424586 @default.
• W2023342930 hasConcept C143998085 @default.
• W2023342930 hasConcept C150903083 @default.
• W2023342930 hasConcept C159654299 @default.
• W2023342930 hasConcept C163864487 @default.
• W2023342930 hasConcept C170493617 @default.
• W2023342930 hasConcept C203014093 @default.
• W2023342930 hasConcept C207001950 @default.
• W2023342930 hasConcept C2778938600 @default.
• W2023342930 hasConcept C2779338263 @default.
• W2023342930 hasConcept C2780868878 @default.
• W2023342930 hasConcept C29730261 @default.
• W2023342930 hasConcept C542903549 @default.
• W2023342930 hasConcept C71924100 @default.
• W2023342930 hasConcept C72563966 @default.
• W2023342930 hasConcept C86803240 @default.
• W2023342930 hasConcept C87355193 @default.
• W2023342930 hasConcept C90924648 @default.
• W2023342930 hasConcept C98274493 @default.
• W2023342930 hasConceptScore W2023342930C112705442 @default.
• W2023342930 hasConceptScore W2023342930C126322002 @default.
• W2023342930 hasConceptScore W2023342930C142424586 @default.
• W2023342930 hasConceptScore W2023342930C143998085 @default.
• W2023342930 hasConceptScore W2023342930C150903083 @default.
• W2023342930 hasConceptScore W2023342930C159654299 @default.

• next